Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
NCT06967558Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of exendin 9-39 in prediabetes, sponsored by Mayo Clinic. Started Nov 2025; status: recruiting.
02
Drugs
exendin 9-39
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT06967558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967558.